Yuan-Mao Lin1,2, Ryosuke Taiji1,3, Marco Calandri4, Bruno C Odisio5. 1. Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler St. FCT 14.5084, Houston, TX, 77030, USA. 2. School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. 3. Department of Radiology, Nara Medical University, Nara, Japan. 4. Radiology Unit, San Luigi Gonzaga University Hospital - Department of Oncology, University of Turin, Turin, Italy. 5. Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler St. FCT 14.5084, Houston, TX, 77030, USA. bcodisio@mdanderson.org.
Abstract
PURPOSE OF REVIEW: Interventional oncology (IO) loco-regional treatments are widely utilized in clinical practice. However, local tumor control rates are still widely variable. There is a need to identify and develop novel biomarkers prognosticators following IO therapies. Here, we review the current literature on molecular tumor biomarkers in IO, mainly focusing on patients with liver and lung cancers. RECENT FINDINGS: RAS mutation is a prognosticator for patients with colorectal liver metastases. Several promising serum metabolites, gene signatures, circulating tumor nucleotides, and peptides are being evaluated for patients with hepatocellular carcinoma. Ki-67 and RAS mutation are independent risk factors for local tumor progression in the ablation of lung cancer. The relevant interplay between specific tumor biomarkers and IO loco-regional therapies outcomes has brought a new vision in the management of cancer. Further evolution of personalized interventional oncology accordingly to tumor biomarkers should improve oncologic outcomes for patients receiving IO therapies.
PURPOSE OF REVIEW: Interventional oncology (IO) loco-regional treatments are widely utilized in clinical practice. However, local tumor control rates are still widely variable. There is a need to identify and develop novel biomarkers prognosticators following IO therapies. Here, we review the current literature on molecular tumor biomarkers in IO, mainly focusing on patients with liver and lung cancers. RECENT FINDINGS: RAS mutation is a prognosticator for patients with colorectal liver metastases. Several promising serum metabolites, gene signatures, circulating tumor nucleotides, and peptides are being evaluated for patients with hepatocellular carcinoma. Ki-67 and RAS mutation are independent risk factors for local tumor progression in the ablation of lung cancer. The relevant interplay between specific tumor biomarkers and IO loco-regional therapies outcomes has brought a new vision in the management of cancer. Further evolution of personalized interventional oncology accordingly to tumor biomarkers should improve oncologic outcomes for patients receiving IO therapies.
Authors: Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni Journal: Cardiovasc Intervent Radiol Date: 2009-11-12 Impact factor: 2.740
Authors: Yong Kang Lee; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang Hun Lee; Do Yun Lee; Kwang-Hyub Han; Chae Yoon Chon; Jun Yong Park Journal: BMC Cancer Date: 2013-01-03 Impact factor: 4.430
Authors: Christina Fitzmaurice; Tomi F Akinyemiju; Faris Hasan Al Lami; Tahiya Alam; Reza Alizadeh-Navaei; Christine Allen; Ubai Alsharif; Nelson Alvis-Guzman; Erfan Amini; Benjamin O Anderson; Olatunde Aremu; Al Artaman; Solomon Weldegebreal Asgedom; Reza Assadi; Tesfay Mehari Atey; Leticia Avila-Burgos; Ashish Awasthi; Huda Omer Ba Saleem; Aleksandra Barac; James R Bennett; Isabela M Bensenor; Nickhill Bhakta; Hermann Brenner; Lucero Cahuana-Hurtado; Carlos A Castañeda-Orjuela; Ferrán Catalá-López; Jee-Young Jasmine Choi; Devasahayam Jesudas Christopher; Sheng-Chia Chung; Maria Paula Curado; Lalit Dandona; Rakhi Dandona; José das Neves; Subhojit Dey; Samath D Dharmaratne; David Teye Doku; Tim R Driscoll; Manisha Dubey; Hedyeh Ebrahimi; Dumessa Edessa; Ziad El-Khatib; Aman Yesuf Endries; Florian Fischer; Lisa M Force; Kyle J Foreman; Solomon Weldemariam Gebrehiwot; Sameer Vali Gopalani; Giuseppe Grosso; Rahul Gupta; Bishal Gyawali; Randah Ribhi Hamadeh; Samer Hamidi; James Harvey; Hamid Yimam Hassen; Roderick J Hay; Simon I Hay; Behzad Heibati; Molla Kahssay Hiluf; Nobuyuki Horita; H Dean Hosgood; Olayinka S Ilesanmi; Kaire Innos; Farhad Islami; Mihajlo B Jakovljevic; Sarah Charlotte Johnson; Jost B Jonas; Amir Kasaeian; Tesfaye Dessale Kassa; Yousef Saleh Khader; Ejaz Ahmad Khan; Gulfaraz Khan; Young-Ho Khang; Mohammad Hossein Khosravi; Jagdish Khubchandani; Jacek A Kopec; G Anil Kumar; Michael Kutz; Deepesh Pravinkumar Lad; Alessandra Lafranconi; Qing Lan; Yirga Legesse; James Leigh; Shai Linn; Raimundas Lunevicius; Azeem Majeed; Reza Malekzadeh; Deborah Carvalho Malta; Lorenzo G Mantovani; Brian J McMahon; Toni Meier; Yohannes Adama Melaku; Mulugeta Melku; Peter Memiah; Walter Mendoza; Tuomo J Meretoja; Haftay Berhane Mezgebe; Ted R Miller; Shafiu Mohammed; Ali H Mokdad; Mahmood Moosazadeh; Paula Moraga; Seyyed Meysam Mousavi; Vinay Nangia; Cuong Tat Nguyen; Vuong Minh Nong; Felix Akpojene Ogbo; Andrew Toyin Olagunju; Mahesh Pa; Eun-Kee Park; Tejas Patel; David M Pereira; Farhad Pishgar; Maarten J Postma; Farshad Pourmalek; Mostafa Qorbani; Anwar Rafay; Salman Rawaf; David Laith Rawaf; Gholamreza Roshandel; Saeid Safiri; Hamideh Salimzadeh; Juan Ramon Sanabria; Milena M Santric Milicevic; Benn Sartorius; Maheswar Satpathy; Sadaf G Sepanlou; Katya Anne Shackelford; Masood Ali Shaikh; Mahdi Sharif-Alhoseini; Jun She; Min-Jeong Shin; Ivy Shiue; Mark G Shrime; Abiy Hiruye Sinke; Mekonnen Sisay; Amber Sligar; Muawiyyah Babale Sufiyan; Bryan L Sykes; Rafael Tabarés-Seisdedos; Gizachew Assefa Tessema; Roman Topor-Madry; Tung Thanh Tran; Bach Xuan Tran; Kingsley Nnanna Ukwaja; Vasiliy Victorovich Vlassov; Stein Emil Vollset; Elisabete Weiderpass; Hywel C Williams; Nigus Bililign Yimer; Naohiro Yonemoto; Mustafa Z Younis; Christopher J L Murray; Mohsen Naghavi Journal: JAMA Oncol Date: 2018-11-01 Impact factor: 31.777